Summit Therapeutics Shares Drop Despite Positive Phase 3 Data on Ivonescimab in NSCLC
Despite positive phase 3 data for ivonescimab as a first-line treatment for non-small cell lung cancer, Summit Therapeutics (SMMT) shares fell by approximately 10% after market close. The HARMONi-6 study showed that the drug combined with chemotherapy reduced risk.
Tickers: $SMMT
Topics: cancer treatment clinical trials market reaction pharmaceuticals